If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
21/09/2026 [08:30:00]
Results 75 to 100 of 174
Absstract of: EP4789663A2
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Absstract of: US12702755B1
A system which provides closed loop insulin administration is disclosed. A closed loop insulin administration system which bases insulin administration on accurate glucose measurements may improve a patient's quality of life.
Absstract of: WO2026164338A1
Provided are a method and an electronic device, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; and displaying a fifth object for inputting an event in response to user interaction with an input component.
Absstract of: WO2026164339A1
A method and an electronic device are provided, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; displaying a fifth object for inputting an event in response to user interaction with an input component; and storing or transmitting to an external electronic device at least one of a first object, a second object, and a third object in response to user interaction with a fourth object.
Absstract of: US20260224809A1
0000 In accordance with one aspect, a medication infusion device is provided that includes a patch pump configured to be removably adhered to a wearer's skin for delivering doses of medication (e.g., insulin) from a cartridge (e.g., a pre-filled cartridge) through a transcutaneous portion. The medication infusion system may include a pumping system configured to advance a plunger in the cartridge to cause medication in the cartridge to be delivered to the patient. The pumping mechanism may be an improved system that reduced errors in medication administration.
Absstract of: AU2025207075A1
The present disclosure provides cells that are competitive with respect to cancer cells, without experiencing starvation or exhaustion, even in glucose-depleted environments. Specifically, the present disclosure provides survivor T cells with enhanced glucose uptake capacity. The T cells are modified so as to express a glucose transporter and/or configured such that the expression of a glucose transporter is enhanced. Also provided are a cell population including such cells, a pharmaceutical composition, and a treatment method.
Absstract of: WO2026161967A1
A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.
Absstract of: AU2025206886A1
The present disclosure provides cells that are competitive to cancer cells without starvation and exhaustion even in an environment in which glucose is depleted. More specifically, the present disclosure provides T cells with enhanced glucose uptake ability, wherein the T cells are modified such that the expression of glucose transporters in the T cells is regulated in response to changes in tumor microenvironmental conditions, and/or the T cells comprise a nucleic acid sequence encoding a glucose transporter operably linked to a tumor microenvironment sensing element that senses changes in tumor microenvironmental conditions.
Absstract of: AU2026206210A1
A continuous glucose measurement apparatus is provided. The continuous glucose measurement apparatus comprises a body attachable unit configured to be inserted into and attached to a body and to measure blood glucose. The body attachable unit comprises: a sensor module including a sensing area formed at an end portion of the sensor module, and a guide needle configured to cover at least a partial area of the sensor module and to move integrally with the sensor module into the body. The guide needle comprises an incision portion formed at a front end portion of the guide needle to incise skin of the body, and an insertion support portion extending from a back portion of the incision portion. In a state in which the body attachable unit is inserted into the body, a depth of an incised portion formed by the insertion support portion of the guide needle is less than an insertion depth of the sensor module. The sensing area is disposed in a region corresponding to the incision portion of the guide needle. ul u l
Absstract of: US20260226424A1
0000 The present invention provides a method for washing lymphocytes, including washing lymphocytes with a bicarbonate ion-containing physiological aqueous solution; a method for cryopreserving lymphocytes, including suspending and freezing lymphocytes obtained by the method in a cryopreservation solution containing a physiological aqueous solution; a washing solution for lymphocytes, including a bicarbonate ion-containing physiological aqueous solution; a cryopreservation solution for lymphocytes, containing a bicarbonate ion-containing physiological aqueous solution, dextran, glucose, DMSO, and human serum albumin; a lymphocyte-containing composition, containing lymphocytes treated with a bicarbonate ion-containing physiological aqueous solution and the aforementioned cryopreservation solution; a kit for preparing lymphocytes for transplantation, containing the lymphocyte-containing composition and a diluent for transplantation containing a bicarbonate ion-containing physiological aqueous solution, and the like.
Absstract of: US20260224480A1
A system for oral delivery of an active ingredient is provided, the system including: a mucoadhesive layer including a mucoadhesive and an active ingredient; and a backing layer extending over the mucoadhesive layer, the backing layer including a bulk agent, the active ingredient being selected from the group consisting of nicotine, caffeine, anatabine, at least one cannabinoid such as tetrahydrocannabinol, and a combination thereof, the system being orally dissolvable, and the bulk agent being selected from the group consisting of at least one mono-, di-, and/or polysaccharide, at least one sugar alcohol, and a combination thereof.
Absstract of: US20260224811A1
The ambulatory infusion pump system of claim 17, wherein the infusion pump does not include a display and includes a bolus button configured to enable programming of a predetermined amount of medicament, and wherein the at least one processor is configured to disable the bolus button when the higher priority interface or lower priority interface has been accessed.The ambulatory infusion pump system of claim 11, wherein the at least one processor is further configured to cause a message to display on the lower priority interface indicating that the lower priority interface is inaccessible due to the higher priority interface having been accessed.The ambulatory infusion pump system of claim 11, wherein the at least one processor is configured to automatically exit the lower priority interface if the lower priority interface is active when the higher priority interface is accessed.In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and/or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and/or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissio
Absstract of: US20260224172A1
Certain aspects of the present disclosure relate to methods and systems for predicting glycemic events in a patient induced as a result of physical activity. In certain aspects, a method includes monitoring a plurality of analytes of the patient continuously during a time period to obtain analyte data, the plurality of analytes including at least glucose and lactate. The method further includes processing the analyte data from the time period to determine an intensity level of physical activity engaged by the patient during the time period. The method further includes generating a glycemic event prediction using at least the analyte data for the plurality of analytes and the determination of physical activity intensity. The method further includes generating one or more recommendations for treatment for the patient based, at least in part, on the glycemic event prediction.
Absstract of: US20260224136A1
0000 An example continuous glucose monitor includes a printed circuit board (“PCB”) having first and second outer layers and an inner layer; a semiconductor package having a plurality of pins coupled to the first outer layer of the PCB; an electrical contact formed on the second outer layer of the PCB; a trace having a first portion disposed on the first outer layer, a second portion disposed on the inner layer, and a third portion disposed on the second outer layer, the trace having a first end coupled to a first pin of the plurality of pins and a second end coupled to the electrical contact; and an encapsulant disposed around a perimeter of the semiconductor package, the encapsulant covering the plurality of pins, the first portion of the sensor trace, the third portion of the sensor trace, wherein an upper surface of the semiconductor package remains exposed.
Absstract of: AU2026206162A1
A glucose monitoring system, comprising: a glucose sensor comprising a portion configured to be positioned in a body of a user in fluid contact with a bodily fluid to sense glucose in the bodily fluid; and sensor electronics coupled to the glucose sensor, the sensor electronics comprising: one or more processors, memory coupled with the one or more processors, and wireless communication circuitry configured to communicate data indicative of glucose levels based on the sensed glucose in the bodily fluid according to a Bluetooth communication protocol; and a reader device comprising: a display; one or more processors; a transceiver configured to receive the data indicative of the glucose levels; a memory coupled to the one or more processors of the reader device and storing instructions that when executed by the one or more processors of the reader device cause the one or more processors of the reader device to: determine a glucose curve based on the data indicative of the glucose levels, wherein the glucose curve is associated with a glucose response to an event, calculate a numerical score for the event, wherein the numerical score is based in part on an area under the glucose curve and a duration of the glucose response to the event, determine a cumulative score comprising a sum of the numerical scores associated with a plurality of events, and output on the display the cumulative score and a target score. ul u l
Absstract of: GB2703647A
A system capable of tracking medicine comprising a locating device attached to the item to be tracked such as an insulin pen. The system may also comprise a smart phone app for connecting with the locating device and receiving the location information, a purpose built plastic container that holds the tracking components and attaches to the device to be tracked, and a light or a means of making sound within the tracking device to alert a user to the location of the item. Figure 1
Absstract of: US2025099674A1
Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.
Absstract of: EP4529835A1
0001 A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention is distinguished by that the radio noise signal is received using a total power radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.
Absstract of: US2025111918A1
0000 Systems and methods are provided including insulin pump systems for determining certain information about a user of a wearable insulin pump based on naturally spoken user data by applying the user data to a large language model (LLM) or other machine learning model to parse the user data into categories. For example, certain rules and/or constraints may be provided to the LLM and may cause the LLM or machine learning model to parse the user data into defined categories that may be used for updating a user record. Categories may include food consumption, activities, sleep, and/or pump operation information, for example. Additional data may be determined from the parsed data such as caloric information, exercise duration, sleep information and the like. The parsed categorized data and/or additional data may be used to adjust operation of the insulin delivery pump.
Absstract of: US2025108160A1
0000 Systems and methods are provided for managing communication with a user of an insulin pump system for improving insulin pump operation and/or a user experience relating to the insulin delivery system. The insulin pump system may analyze data from a user of a certain insulin pump and/or data from users of different insulin pumps and determine patterns relating to such use and indicative of certain user experiences. Based on the detected patterns and/or events associated with the patterns or user experiences, user messages may be proactively sent a user device and/or smart device of the user. The user messages may be designed to improve a user experience and/or prevent a negative outcome. For example, a message may be a training video, may include a reminder to adjust pump operation for a certain activity, and/or may include an alert to reorder more supplies.
Absstract of: USRE50976E
A wearable diagnostic device worn on a user's body that can provide various types of health-related information to the user is described. The wearable diagnostic device can provide real-time, non-invasive, accurate, and continuous data regarding a user's heart rate, hemoglobin level, body temperature, oxygen level, glucose level, and blood pressure. In some implementations, the wearable diagnostic device may also provide electrocardiogram (EKG) data or detection of Parkinson's symptoms, such as the involuntary movement of a user's hand. A user may configure the wearable diagnostic device to provide information on one, multiple, or all of the health-related information noted above.
Absstract of: CN122478863A
The invention relates to a construction method of a nano-enzyme engineered exosome and application of the nano-enzyme engineered exosome in diabetic bone defect repair. The method comprises the following steps: preparing an exosome M2-Exo which is derived from M2 macrophages and has a mercaptan functionalized surface; the preparation method comprises the following steps: modifying Mn3O4 antioxidant nano enzyme by using a DSPE-PEG-Mal solution, so as to obtain maleimide functionalized Mn3O4; and mixing the maleimide functionalized Mn3O4 solution with the surface mercaptan functionalized exosome M2-Exo solution, and after the reaction is completed, carrying out post-treatment to obtain the engineered exosome Mn3O4 (at) M2E. According to the preparation method disclosed by the invention, a trimanganese tetroxide nano enzyme is coupled to the surface of M < 2-> Exo through a thiol-maleimide reaction, so that the Mn3O4 (at) M < 2 > E engineered exosome is prepared. By inhibiting the inflammation amplification effect mediated by the NETosis process and synchronously inducing the macrophages to be polarized to the anti-inflammatory M2 phenotype, the innate immune microenvironment is remodeled. Finally, the microenvironment of harmful inflammation of diabetes is successfully reversed into a regeneration promoting state beneficial to tissue repair.
Absstract of: CN122479193A
The invention relates to the technical field of hydrogel, in particular to wearable hydrogel for monitoring and treating diabetic wounds and a preparation method thereof.The wearable hydrogel for monitoring and treating the diabetic wounds is composed of a nano-composite hydrogel dressing matrix and a flexible physiological monitoring sensing unit, and the dressing matrix takes a mixed solution of carboxymethyl chitosan and polyvinyl alcohol as a basic matrix; chitosan coated mesoporous silica-cerium oxide loaded epigallocatechin gallate nanoparticles and bismuth selenide nanosheets are dispersed in the hydrogel matrix, the sensing unit is composed of a pH sensor and a uric acid sensor and is integrated on the surface of the hydrogel matrix, and integration of monitoring and treatment of diabetic wounds is achieved. The hydrogel is good in adhesion, good in moisture retention, capable of slowly releasing active ingredients in a long-acting mode, resistant to oxidation, capable of achieving photo-thermal antibiosis and excellent in antibacterial effect, wound indexes can be monitored in a non-invasive mode in real time through the integrated double sensing units, detection is stable under mechanical deformation, a reliable basis is provided for wound diagnosis and treatment, and diagnosis and treatment integration is achieved.
Absstract of: CN122497461A
The invention discloses a measurement method, system and related device, the method is applied to first electronic equipment, the first electronic equipment comprises a first electrode group and a second electrode group, and the distance between the first electrode group and the second electrode group is greater than a first distance; under the condition that a first electrode group and a second electrode group are implanted into subcutaneous tissue, the method comprises the following steps: determining a first physiological parameter through the first electrode group; electrocardiosignals are determined through the first electrode set and the second electrode set. Therefore, the electrocardiosignal of the user can be obtained anytime and anywhere through the first electronic equipment, and one or more other physiological parameters (such as blood glucose, blood ketone, blood lactic acid and uric acid) of the user can be measured at the same time, so that the health monitoring efficiency is improved.
Nº publicación: CN122478500A 31/07/2026
Applicant:
HANGZHOU INST OF OPTICS AND FINE MECHANICS
\u676D\u5DDE\u5149\u5B66\u7CBE\u5BC6\u673A\u68B0\u7814\u7A76\u6240
Absstract of: CN122478500A
The invention relates to the technical field of force, stress or pressure measurement, in particular to a diabetes high-risk foot sole monitoring method and device and a storage medium, and the method comprises the steps: obtaining multi-pixel foot sole stress data and/or multi-pixel foot sole pressure data collected by a flexible electronic skin array in a plurality of gait cycles; generating a continuous plantar pressure mapping graph; determining a pressure center track and a high-pressure area migration track in each gait cycle; constructing a plantar pressure transfer baseline; determining a pressure transfer abnormal offset feature of the current gait cycle; determining a local high-pressure continuous region corresponding to the pressure transfer abnormal offset feature; and inputting a diabetes high-risk foot risk assessment model, and outputting an abnormal load area and a risk early warning level. According to the invention, the problem that the existing diabetes high-risk foot sole monitoring technology is difficult to accurately identify the local abnormal load risk based on the individualized dynamic pressure transfer rule is effectively solved.
BOPI
Electronic site
